Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
12/10/18 GEM051 Protective agents from heat stress Heatstroke Oral Preclinical Suppression of vascular endothelial cell damage and production and release of inflammatory cytokines from blood cells due to heat stress.
Ingredients derived from citrus fruit extract.
11/22/18 GEM050 Curcumin analogue CML, Pancreatic cancer, glioblastoma etc. Oral Preclinical Inhibited proliferation of CML and pancreatic cancer cells at the submicromolar level.
Unlike imatinib, the inhibitory action is irreversible.
Suppressed almost completely human CML cell growth without significant changes in body weight and peripheral white blood cell count in vivo.
An incease in ROS/RCS produced by inhibition of their scavenging enzymes is assumed to be involved in anti-tumor action.
Induced M phase arrest.
11/15/18 GEM049 Pan-NOX inhibitor IBD, Neuro- degenerative diseases Oral Preclinical Highly potent NOX inhibitor : 20-50 times more potent than GKT-137831.
Significant effects in DNBS-ulcerative colitis and LPS-induced acute inflammatory animal studies.
High oral bioavailability and clean off-targets profile.
11/15/18 GEM048 Inhibition of microbe-specific activation of B2 cells Arterio- sclerosis Discovery Activation of B2 cells induced by changes of intestinal microbiota is involved in the development of atherosclerosis with a different mechanism from lipid metabolism.
Disruption of intestinal microbiota or depletion of activated B2 cells suppressed the development of atherosclerosis in mouse model.
10/25/18 GEM047 Lactoferrin complexes Pain on Peripheral Neuropathy, Cancer IV Preclinical Improved PK profile over natural lactoferrin.
Analgesic effect on periferal neuropathy induced by oxaliplatin.
Inhibitory effects on the growth of syngeneic murine lung cancer model
Inhibitory effects on the growth of human non-small cell lung cancer cell in vitro.
Positive effect of treatment on sepsis mice model.
10/25/18 GEM046 Indirect activator of AMPK Hyper- lipidemia, type 2 diabetes, cancer Oral Preclinical Derivative of fungus product ascochlorin.
Good PK profile in rats.
Superior effects than metformin on blood glucose and triglyceride level in diabetic mice model.
Significant enhancement of the efficacy in combination with metformin on T2D model
Significant enhancement of the antitumor activity of anti-PD-1 antibody in mouse model
09/20/18 GEM045 Autotaxin Inhibitor NASH, Panacreatic cancer Oral Preclinical Showed antifibrotic efficacy with significant histopathological score reductions in chronic pancreatitis and NASH (Stelic STAM & MCD) in mice.
Showed significant anti-inflammatory effects in paw edema animal study.
09/20/18 GEM044 TLR4-NOX dual inhibitor AIH, Pancreatic cancer and IBD Oral Preclinical 5-10 times more potent on NOX activity than GKT-137831.
Hepatoprotection with significant reductions on ALT/AST in AIH in mice.
Showed antifibrotic efficacy with significant histopathological score reductions in caerulein-induced pancreatic fibrosis in mice.
Showed antifibrotic efficacy with significant NAS reductions in Stelic-STAM (NASH) in mice.
09/20/18 GEM042 TLR4 antagonist NAFLD, AIH, CLD and CD Oral Phase 2 NAFLD (nonalcoholic fatty liver disease): The phase 2 results demonstrated significant improvement on relevant diagnosis and biomarkers.
AIH (autoimmune hepatitis; orphan designation): The phase 2 (open label) results will be available soon.
CLD(chronic liver disease by HCV infection): A strong trend of improvement of liver function and safety in Phase 2.
CD (Crohn's disease): Good efficacy in three Phase 2 POC studies.
The drug is safe and tolerable in these trials.
09/20/18 GEM041 Dual inhibitor of catechol-O-methyltransferase and dopa decarboxylase Parkinson's disease Oral Preclinical First dual inhibitor in the World.
Almost same inhibitory activities for the two enzymes.
The enzyme activities were inhibited strongly in the liver, but not in the brain.